BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM; American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-35. [PMID: 19521341 DOI: 10.1038/ajg.2008.122] [Cited by in Crossref: 177] [Cited by in F6Publishing: 282] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhang T, Ma X, Tian W, Zhang J, Wei Y, Zhang B, Wang F, Tang X. Global Research Trends in Irritable Bowel Syndrome: A Bibliometric and Visualized Study. Front Med 2022;9:922063. [DOI: 10.3389/fmed.2022.922063] [Reference Citation Analysis]
2 Gemcioglu E, Yılmaz Cakmak N, Baser S, Kocaoz S, Ersoy O. Factors affecting the use of herbal products in patients with Irritable Bowel Syndrome and their results: case-control study. BMC Gastroenterol 2022;22:43. [PMID: 35120448 DOI: 10.1186/s12876-022-02125-z] [Reference Citation Analysis]
3 Lin H, Guo Q, Wen Z, Tan S, Chen J, Lin L, Chen P, He J, Wen J, Chen Y. The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors. Microb Cell Fact 2021;20:233. [PMID: 34963452 DOI: 10.1186/s12934-021-01720-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Jacobs JP, Gupta A, Bhatt RR, Brawer J, Gao K, Tillisch K, Lagishetty V, Firth R, Gudleski GD, Ellingson BM, Labus JS, Naliboff BD, Lackner JM, Mayer EA. Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome 2021;9:236. [PMID: 34847963 DOI: 10.1186/s40168-021-01188-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Biruete A, Shin A, Kistler BM, Moe SM. Feeling gutted in chronic kidney disease (CKD): Gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis. Semin Dial 2021. [PMID: 34708456 DOI: 10.1111/sdi.13030] [Reference Citation Analysis]
6 Zhou HH, Zhang YM, Zhang SP, Xu QX, Tian YQ, Li P, Cao D, Zheng YQ. Suppression of PTRF Alleviates Post-Infectious Irritable Bowel Syndrome via Downregulation of the TLR4 Pathway in Rats. Front Pharmacol 2021;12:724410. [PMID: 34690766 DOI: 10.3389/fphar.2021.724410] [Reference Citation Analysis]
7 Wu YB, Dai YK, Zhang L, Pan HG, Chen WJ, Li RL, Hu L. Pharmacological treatments of Chinese herbal medicine for irritable bowel syndrome in adults: A network meta-analysis of randomized controlled trials. PLoS One 2021;16:e0255665. [PMID: 34358263 DOI: 10.1371/journal.pone.0255665] [Reference Citation Analysis]
8 Chen HH, Hung CH, Kao AW, Hsieh HF. Exploring Quality of Life, Stress, and Risk Factors Associated with Irritable Bowel Syndrome for Female University Students in Taiwan. Int J Environ Res Public Health 2021;18:3888. [PMID: 33917268 DOI: 10.3390/ijerph18083888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Raahave D, Jensen AK. Increased colon transit time and faecal load in irritable bowel syndrome. World J Gastrointest Pharmacol Ther 2021; 12(1): 13-20 [PMID: 33564493 DOI: 10.4292/wjgpt.v12.i1.13] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wu J, Fu Q, Yang S, Wang H, Li Y. Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2020;2020:5812320. [PMID: 33354220 DOI: 10.1155/2020/5812320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, Vitt D. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. World J Gastrointest Pathophysiol 2020; 11(6): 114-130 [PMID: 33362939 DOI: 10.4291/wjgp.v11.i6.114] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Li YL, Yao CJ, Lei R, Xie F, Xiong Q, Luo LH, Feng PM. Acupuncture combined with Tongxieyaofang for diarrhea-type irritable bowel syndrome: A protocol for meta-analysis. Medicine (Baltimore) 2020;99:e23457. [PMID: 33235133 DOI: 10.1097/MD.0000000000023457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Bordbar G, Miri MB, Omidi M, Shoja S, Akhavan M. Comparison of a Novel Herbal Medicine and Omeprazole in the Treatment of Functional Dyspepsia: A Randomized Double-Blinded Clinical Trial. Gastroenterol Res Pract 2020;2020:5152736. [PMID: 33273914 DOI: 10.1155/2020/5152736] [Reference Citation Analysis]
14 Dai YK, Wu YB, Li RL, Chen WJ, Tang CZ, Lu LM, Hu L. Efficacy and safety of non-pharmacological interventions for irritable bowel syndrome in adults. World J Gastroenterol 2020; 26(41): 6488-6509 [PMID: 33244207 DOI: 10.3748/wjg.v26.i41.6488] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Polunina TE. Irritable bowel syndrome and biliary tract pathology. Clinical analysis. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-15-28-38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Moayyedi P, MacQueen G, Bernstein CN, Vanner S, Bercik P, Madsen KL, Surette M, Rioux JD, Dieleman LA, Verdú E, de Souza RJ, Otley A, Targownik L, Lavis J, Cunningham J, Marshall DA, Zelinsky S, Fernandes A. IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open 2020;10:e041733. [PMID: 33087380 DOI: 10.1136/bmjopen-2020-041733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Zeevenhooven J, de Bruijn CMA, Vlieger A, Nieuwdorp M, Benninga MA. Protocol for a pilot randomised, double-blind, placebo-controlled trial for assessing the feasibility and efficacy of faecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: FAIS Trial. BMJ Paediatr Open 2020;4:e000689. [PMID: 32864480 DOI: 10.1136/bmjpo-2020-000689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Bazarganipour F, Taghavi SA, Asemi Z, Allan H, Khashavi Z, Safarzadeh T, Pourchangiz S, Zare F, Ghasemi S, Karimi Z, Azizi Kutenaee M. The impact of irritable bowel syndrome on health-related quality of life in women with polycystic ovary syndrome. Health Qual Life Outcomes 2020;18:226. [PMID: 32660493 DOI: 10.1186/s12955-020-01428-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sierżantowicz R, Lewko J, Jurkowska G. The Impact of an Individual Educational Program on the Quality of Life and Severity of Symptoms of Patients with Irritable Bowel Syndrome. Int J Environ Res Public Health 2020;17:E4230. [PMID: 32545800 DOI: 10.3390/ijerph17124230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Milutinović M, Branković S, Ćujić N, Šavikin K, Kostić M, Kitić N, Miladinović B, Kitić D. Antispasmodic effects of black chokeberry (Aronia melanocarpa (Michx.) Elliott) extracts and juice and their potential use in gastrointestinal disorders. JBR 2020;10:175-92. [DOI: 10.3233/jbr-190435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bordbar G, Miri MB, Omidi M, Shoja S, Akhavan M. Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial. Gastroenterol Res Pract 2020;2020:8213082. [PMID: 32565786 DOI: 10.1155/2020/8213082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Shin SY, Cha BK, Kim WS, Park JY, Kim JW, Choi CH. The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. J Neurogastroenterol Motil 2020;26:117-27. [PMID: 31917916 DOI: 10.5056/jnm19160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
23 Bellini M, Tonarelli S, Nagy AG, Pancetti A, Costa F, Ricchiuti A, de Bortoli N, Mosca M, Marchi S, Rossi A. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients 2020;12:E148. [PMID: 31947991 DOI: 10.3390/nu12010148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
24 Zheng H, Chen R, Zhao X, Li G, Liang Y, Zhang H, Chi Z. Comparison between the Effects of Acupuncture Relative to Other Controls on Irritable Bowel Syndrome: A Meta-Analysis. Pain Res Manag 2019;2019:2871505. [PMID: 31814859 DOI: 10.1155/2019/2871505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
25 Hadjivasilis A, Tsioutis C, Michalinos A, Ntourakis D, Christodoulou DK, Agouridis AP. New insights into irritable bowel syndrome: from pathophysiology to treatment. Ann Gastroenterol 2019;32:554-64. [PMID: 31700231 DOI: 10.20524/aog.2019.0428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
26 Fodor I, Man SC, Dumitrascu DL. Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet in children. World J Clin Cases 2019; 7(18): 2666-2674 [PMID: 31616683 DOI: 10.12998/wjcc.v7.i18.2666] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Kim SB, Calmet FH, Garrido J, Garcia-Buitrago MT, Moshiree B. Sucrase-Isomaltase Deficiency as a Potential Masquerader in Irritable Bowel Syndrome. Dig Dis Sci 2020;65:534-40. [PMID: 31493040 DOI: 10.1007/s10620-019-05780-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
28 Brown SC, Whelan K, Gearry RB, Day AS. Low FODMAP diet in children and adolescents with functional bowel disorder: A clinical case note review. JGH Open 2020;4:153-9. [PMID: 32280758 DOI: 10.1002/jgh3.12231] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
29 Huang HL, Chen HT, Luo QL, Xu HM, He J, Li YQ, Zhou YL, Yao F, Nie YQ, Zhou YJ. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. J Dig Dis. 2019;20:401-408. [PMID: 31070838 DOI: 10.1111/1751-2980.12756] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
30 Trott N, Aziz I, Rej A, Surendran Sanders D. How Patients with IBS Use Low FODMAP Dietary Information Provided by General Practitioners and Gastroenterologists: A Qualitative Study. Nutrients 2019;11:E1313. [PMID: 31212668 DOI: 10.3390/nu11061313] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
31 Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018;93:1858-1872. [PMID: 30522596 DOI: 10.1016/j.mayocp.2018.04.032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
32 Yan J, Miao ZW, Lu J, Ge F, Yu LH, Shang WB, Liu LN, Sun ZG. Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2019;2019:7680963. [PMID: 31110553 DOI: 10.1155/2019/7680963] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
33 Fani M, Mostamand J, Fani M, Chitsaz N, Feizi A. The effect of aerobic exercises among women with mild and moderate irritable bowel syndrome: A pilot study. Journal of Bodywork and Movement Therapies 2019;23:161-5. [DOI: 10.1016/j.jbmt.2018.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Han BY, Shao QF, Cong Y, Guo S, Mao XY, Wei RH, Wei W. Transcutaneous electric nerve stimulation over acupoints for patients with diarrhea-predominant irritable bowel syndrome: Protocol for systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e13267. [PMID: 30572430 DOI: 10.1097/MD.0000000000013267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Mascarenhas-Saraiva MJ, Mascarenhas-Saraiva M. Effectiveness and tolerability of linaclotide in the treatment of IBS-C in a "real-life" setting: Results from a Portuguese single-center study. Neurogastroenterol Motil 2019;31:e13508. [PMID: 30569519 DOI: 10.1111/nmo.13508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Kavanagh RG, O’Grady J, Carey BW, O’Connor OJ, Maher MM. Review of the role of abdominal imaging in irritable bowel syndrome. World J Radiol 2018; 10(11): 143-149 [PMID: 30568748 DOI: 10.4329/wjr.v10.i11.143] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Yim SK, Kim SW. Refractory Irritable Bowel Syndrome and Functional Abdominal Pain Syndrome: Should Small Bowel Endoscopy Be Performed? Clin Endosc 2018;51:508-9. [PMID: 30408947 DOI: 10.5946/ce.2018.157] [Reference Citation Analysis]
38 Peng Y, You H, Chen X, Chen Y, Yang Y, Huang J, Xu N, Liu J. Effect of electroacupuncture at homotopic and heterotopic acupoints on abdominal pain in patients with irritable bowel syndrome: study protocol for a randomized controlled trial. Trials 2018;19:559. [PMID: 30326940 DOI: 10.1186/s13063-018-2948-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Menezes LAA, Minervini F, Filannino P, Sardaro MLS, Gatti M, Lindner JD. Effects of Sourdough on FODMAPs in Bread and Potential Outcomes on Irritable Bowel Syndrome Patients and Healthy Subjects. Front Microbiol 2018;9:1972. [PMID: 30186276 DOI: 10.3389/fmicb.2018.01972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
40 Zhang QE, Wang F, Qin G, Zheng W, Ng CH, Ungvari GS, Yuan Z, Mei S, Wang G, Xiang YT. Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies. Int J Biol Sci. 2018;14:1504-1512. [PMID: 30263003 DOI: 10.7150/ijbs.25001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
41 Almazar AE, Talley NJ, Larson JJ, Atkinson EJ, Murray JA, Saito YA. Celiac disease is uncommon in irritable bowel syndrome in the USA. Eur J Gastroenterol Hepatol 2018;30:149-54. [PMID: 29240001 DOI: 10.1097/MEG.0000000000001022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
42 Li Q, Zhang BP, Huang SG, Ouyang WW, Xie JH, Wen ZH, Yang XB. Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial. Trials 2018;19:367. [PMID: 29996882 DOI: 10.1186/s13063-018-2754-9] [Reference Citation Analysis]
43 Luty J. Medically unexplained syndromes: irritable bowel syndrome, fibromyalgia and chronic fatigue. BJPsych advances 2018;24:252-63. [DOI: 10.1192/bja.2017.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Testa A, Imperatore N, Rispo A, Rea M, Tortora R, Nardone OM, Lucci L, Accarino G, Caporaso N, Castiglione F. Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease. Dig Dis. 2018;36:271-280. [PMID: 29763907 DOI: 10.1159/000489487] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
45 Daghaghzadeh H, Memar A, Mohamadi Y, Rezakhani N, Safazadeh P, Aghaha S, Adibi P. Therapeutic Effects of Low-dose Bismuth Subcitrate on Symptoms and Health-related Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial. J Res Pharm Pract 2018;7:13-21. [PMID: 29755994 DOI: 10.4103/jrpp.JRPP_17_56] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Song KH, Jung HK, Kim HJ, Koo HS, Kwon YH, Shin HD, Lim HC, Shin JE, Kim SE, Cho DH, Kim JH, Kim HJ; Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. J Neurogastroenterol Motil. 2018;24:197-215. [PMID: 29605976 DOI: 10.5056/jnm17145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
47 Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Seifert B, Wensaas KA, Winchester C, de Wit N; European Society for Primary Care Gastroenterology. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther 2018;47:1054-70. [PMID: 29460487 DOI: 10.1111/apt.14539] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 18.3] [Reference Citation Analysis]
48 Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2018;8:2964. [PMID: 29445178 DOI: 10.1038/s41598-018-21241-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
49 Dai YK, Li DY, Zhang YZ, Huang MX, Zhou YL, Ye JT, Wang Q, Hu L. Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials. PLoS One 2018;13:e0192319. [PMID: 29408906 DOI: 10.1371/journal.pone.0192319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
50 Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018;162:1-9. [PMID: 29358788 DOI: 10.5507/bp.2017.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
51 Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet 2018;31:239-55. [DOI: 10.1111/jhn.12530] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 24.3] [Reference Citation Analysis]
52 Torres MJ, Sabate JM, Bouchoucha M, Buscail C, Hercberg S, Julia C. Food consumption and dietary intakes in 36,448 adults and their association with irritable bowel syndrome: Nutrinet-Santé study. Therap Adv Gastroenterol 2018;11:1756283X17746625. [PMID: 29399039 DOI: 10.1177/1756283X17746625] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
53 Senderovich H, Vierhout MJ. Is there a role for charcoal in palliative diarrhea management? Curr Med Res Opin 2018;34:1253-9. [PMID: 29231746 DOI: 10.1080/03007995.2017.1416345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
54 Qi Q, Zhang Y, Chen F, Zuo X, Li Y. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol 2018;18:5. [PMID: 29310568 DOI: 10.1186/s12876-017-0734-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
55 Craven LJ, Silverman M, Burton JP. Transfer of altered behaviour and irritable bowel syndrome with diarrhea (IBS-D) through fecal microbiota transplant in mouse model indicates need for stricter donor screening criteria. Ann Transl Med 2017;5:490. [PMID: 29299452 DOI: 10.21037/atm.2017.10.03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
56 Wortmann AC, Simon D, Mazzoleni LE, Sander GB, Francesconi CFM, Nabinger DD, Grott CS, Rech TF, Mazzoleni F, Lunge VR, Bona LR, Milbradt TC, Silveira TRD. The association between adult-type hypolactasia and symptoms of functional dyspepsia. Genet Mol Biol 2018;41:92-7. [PMID: 29384557 DOI: 10.1590/1678-4685-GMB-2017-0015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
57 Li DY, Dai YK, Zhang YZ, Huang MX, Li RL, Ou-Yang J, Chen WJ, Hu L. Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome. PLoS One 2017;12:e0189491. [PMID: 29253850 DOI: 10.1371/journal.pone.0189491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
58 Kim JY, Park YJ, Lee HJ, Park MY, Kwon O. Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial. Food Sci Biotechnol 2018;27:853-7. [PMID: 30263811 DOI: 10.1007/s10068-017-0296-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
59 Fan WJ, Xu D, Chang M, Zhu LM, Fei GJ, Li XQ, Fang XC. Predictors of healthcare-seeking behavior among Chinese patients with irritable bowel syndrome. World J Gastroenterol 2017; 23(42): 7635-7643 [PMID: 29204063 DOI: 10.3748/wjg.v23.i42.7635] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. J Clin Med 2017;6:E101. [PMID: 29077050 DOI: 10.3390/jcm6110101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
61 Piper MS, Saad RJ. Diabetes Mellitus and the Colon. Curr Treat Options Gastroenterol. 2017;15:460-474. [PMID: 29063998 DOI: 10.1007/s11938-017-0151-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
62 Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J Gastroenterol 2017; 23(37): 6788-6801 [PMID: 29085223 DOI: 10.3748/wjg.v23.i37.6788] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
63 Gudleski GD, Satchidanand N, Dunlap LJ, Tahiliani V, Li X, Keefer L, Lackner JM; IBSOS Outcome Study Research Group. Predictors of medical and mental health care use in patients with irritable bowel syndrome in the United States. Behav Res Ther 2017;88:65-75. [PMID: 28110677 DOI: 10.1016/j.brat.2016.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
64 Gupta K, Ghuman HS, Handa SV. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile. Clin Med Insights Gastroenterol 2017;10:1179552217728905. [PMID: 28894393 DOI: 10.1177/1179552217728905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
65 Altobelli E, Del Negro V, Angeletti PM, Latella G. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients. 2017;9. [PMID: 28846594 DOI: 10.3390/nu9090940] [Cited by in Crossref: 113] [Cited by in F6Publishing: 83] [Article Influence: 22.6] [Reference Citation Analysis]
66 Tuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. Am J Gastroenterol 2018;113:124-34. [PMID: 28809383 DOI: 10.1038/ajg.2017.245] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
67 Wong WM. Restriction of FODMAP in the management of bloating in irritable bowel syndrome. Singapore Med J 2016;57:476-84. [PMID: 27664186 DOI: 10.11622/smedj.2016152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kim HJ, Cha RR, Kim HJ. Understanding the Rome IV: Irritable Bowel Syndrome and Functional Diarrhea. Korean J Med 2017;92:366-71. [DOI: 10.3904/kjm.2017.92.4.366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
69 Jang A, Hwang SK, Padhye NS, Meininger JC. Effects of Cognitive Behavior Therapy on Heart Rate Variability in Young Females with Constipation-predominant Irritable Bowel Syndrome: A Parallel-group Trial. J Neurogastroenterol Motil 2017;23:435-45. [PMID: 28480684 DOI: 10.5056/jnm17017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
70 Kinsinger SW. Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol Res Behav Manag 2017;10:231-7. [PMID: 28790872 DOI: 10.2147/PRBM.S120817] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
71 Harvie RM, Chisholm AW, Bisanz JE, Burton JP, Herbison P, Schultz K, Schultz M. Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World J Gastroenterol 2017; 23(25): 4632-4643 [PMID: 28740352 DOI: 10.3748/wjg.v23.i25.4632] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 65] [Article Influence: 15.4] [Reference Citation Analysis]
72 Rezaie A, Park SC, Morales W, Marsh E, Lembo A, Kim JH, Weitsman S, Chua KS, Barlow GM, Pimentel M. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci 2017;62:1480-5. [PMID: 28451914 DOI: 10.1007/s10620-017-4585-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
73 Flik CE, Bakker L, Laan W, van Rood YR, Smout AJPM, de Wit NJ. Systematic review: The placebo effect of psychological interventions in the treatment of irritable bowel syndrome. World J Gastroenterol 2017; 23(12): 2223-2233 [PMID: 28405151 DOI: 10.3748/wjg.v23.i12.2223] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
74 Ghadir MR, Poradineh M, Sotodeh M, Ansari R, Kolahdoozan S, Hormati A, Yousefi MH, Mirzaei S, Vahedi H. Mesalazine Has No Effect on Mucosal Immune Biomarkers in Patients with Diarrhea-Dominant Irritable Bowel Syndrome Referred to Shariati Hospital: A Randomized Double-Blind, Placebo-Controlled Trial. Middle East J Dig Dis 2017;9:20-5. [PMID: 28316762 DOI: 10.15171/mejdd.2016.47] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
75 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort J, Peña E, Cañones P, Júdez J. Guía de práctica clínica del síndrome del intestino irritable con estreñimiento y estreñimiento funcional en adultos: tratamiento. (Parte 2 de 2). SEMERGEN - Medicina de Familia 2017;43:123-40. [DOI: 10.1016/j.semerg.2017.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
76 Mearin F, Ciriza C, Mínguez M, Rey E, Mascort JJ, Peña E, Cañones P, Júdez J; en nombre de la SEPD, la semFYC, la SEMERGEN y la SEMG. [Irritable bowel syndrome with constipation and functional constipation in adults: Treatment (Part 2 of 2)]. Aten Primaria 2017;49:177-94. [PMID: 28238460 DOI: 10.1016/j.aprim.2017.01.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Portincasa P, Bonfrate L, de Bari O, Lembo A, Ballou S. Irritable bowel syndrome and diet. Gastroenterol Rep (Oxf). 2017;5:11-19. [PMID: 28110300 DOI: 10.1093/gastro/gow047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
78 Boeckxstaens GE, Wouters MM. Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome. Neurogastroenterol Motil. 2017;29. [PMID: 28027594 DOI: 10.1111/nmo.13007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
79 Lauriello M, Eibenstein A, Angelone AM, Pasqua M, Tucci C, Di Giacomo C, Salerno A, Frieri G, Fusetti M. Association between vasomotor rhinitis and irritable bowel syndrome. Allergy Rhinol (Providence) 2016;7:249-55. [PMID: 28683253 DOI: 10.2500/ar.2016.7.0184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Lee J, Lee EH, Moon SH. A systematic review of measurement properties of the instruments measuring health-related quality of life in patients with irritable bowel syndrome. Qual Life Res 2016;25:2985-95. [PMID: 27686797 DOI: 10.1007/s11136-016-1421-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Cash BD. Eluxadoline: a promising therapy that raises many questions. Transl Gastroenterol Hepatol 2016;1:76. [PMID: 28138642 DOI: 10.21037/tgh.2016.09.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
82 de Bortoli N, Frazzoni L, Savarino EV, Frazzoni M, Martinucci I, Jania A, Tolone S, Scagliarini M, Bellini M, Marabotto E, Furnari M, Bodini G, Russo S, Bertani L, Natali V, Fuccio L, Savarino V, Blandizzi C, Marchi S. Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. Am J Gastroenterol 2016;111:1711-7. [PMID: 27644732 DOI: 10.1038/ajg.2016.432] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
83 Broad J, Maurel D, Kung VW, Hicks GA, Schemann M, Barnes MR, Kenakin TP, Granier S, Sanger GJ. Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design. Sci Rep 2016;6:30797. [PMID: 27492592 DOI: 10.1038/srep30797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
84 Raskov H, Burcharth J, Pommergaard HC, Rosenberg J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes. 2016;7:365-383. [PMID: 27472486 DOI: 10.1080/19490976.2016.1218585] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 9.8] [Reference Citation Analysis]
85 Juul JS, Bro F, Hornung N, Andersen BS, Laurberg S, Olesen F, Vedsted P. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design. BMC Cancer 2016;16:445. [PMID: 27400657 DOI: 10.1186/s12885-016-2477-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Sonu I, Triadafilopoulos G, Gardner JD. Persistent constipation and abdominal adverse events with newer treatments for constipation. BMJ Open Gastroenterol 2016;3:e000094. [PMID: 27486521 DOI: 10.1136/bmjgast-2016-000094] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
87 Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2016;17:1395-402. [PMID: 27267380 DOI: 10.1080/14656566.2016.1182982] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
88 Tang B, Zhang J, Yang Z, Lu Y, Xu Q, Chen X, Lin J. Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2016;2016:5105108. [PMID: 27293460 DOI: 10.1155/2016/5105108] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
89 Sobolewska-Włodarczyk A, Włodarczyk M, Storr M, Fichna J. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Ther Clin Risk Manag 2016;12:771-5. [PMID: 27257381 DOI: 10.2147/TCRM.S83722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
90 Spencer M, Gupta A, Dam LV, Shannon C, Menees S, Chey WD. Artificial Sweeteners: A Systematic Review and Primer for Gastroenterologists. J Neurogastroenterol Motil 2016;22:168-80. [PMID: 26932837 DOI: 10.5056/jnm15206] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
91 Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. [PMID: 27159638 DOI: 10.1038/nrdp.2016.14] [Cited by in Crossref: 338] [Cited by in F6Publishing: 394] [Article Influence: 56.3] [Reference Citation Analysis]
92 Bang CS, Kim YS, Han JH, Lee YS, Baik GH, Kim JB, Suk KT, Yoon JH, Kim DJ. Functional Gastrointestinal Disorders in Young Military Men. Gut Liver 2015;9:509-15. [PMID: 25473077 DOI: 10.5009/gnl14109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
93 Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9:354-75. [PMID: 27134665 DOI: 10.1177/1756283X16633050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
94 Lee EH, Kwon O, Hahm KB, Kim W, Kim JI, Cheung DY, Kim YJ, Kim JH, Park JJ, Joo MK. Irritable bowel syndrome-specific health-related quality of life instrument: development and psychometric evaluation. Health Qual Life Outcomes. 2016;14:22. [PMID: 26882900 DOI: 10.1186/s12955-016-0423-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
95 Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015;9:318-331. [PMID: 25918261 DOI: 10.5009/gnl14344] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
96 Makharia A, Catassi C, Makharia GK. The Overlap between Irritable Bowel Syndrome and Non-Celiac Gluten Sensitivity: A Clinical Dilemma. Nutrients 2015;7:10417-26. [PMID: 26690475 DOI: 10.3390/nu7125541] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
97 Nusrat S, Miner PB Jr. New pharmacological treatment options for irritable bowel syndrome with constipation. Expert Opin Emerg Drugs. 2015;20:625-636. [PMID: 26548544 DOI: 10.1517/14728214.2015.1105215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
98 Nee J, Zakari M, Lembo AJ. Novel Therapies in IBS-D Treatment. Curr Treat Options Gastroenterol 2015;13:432-40. [PMID: 26432092 DOI: 10.1007/s11938-015-0068-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
99 Bellini M, Gambaccini D, Usai-Satta P, De Bortoli N, Bertani L, Marchi S, Stasi C. Irritable bowel syndrome and chronic constipation: Fact and fiction. World J Gastroenterol 2015; 21(40): 11362-11370 [PMID: 26523103 DOI: 10.3748/wjg.v21.i40.11362] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
100 Iacovou M, Tan V, Muir JG, Gibson PR. The Low FODMAP Diet and Its Application in East and Southeast Asia. J Neurogastroenterol Motil. 2015;21:459-470. [PMID: 26350937 DOI: 10.5056/jnm15111] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
101 Barboza JL, Talley NJ, Moshiree B. Current and emerging pharmacotherapeutic options for irritable bowel syndrome. Drugs 2014;74:1849-70. [PMID: 25260888 DOI: 10.1007/s40265-014-0292-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
102 Chira A, Dumitrascu DL. Serum biomarkers for irritable bowel syndrome. Clujul Med 2015;88:258-64. [PMID: 26609254 DOI: 10.15386/cjmed-496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
103 Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015;57:129-134. [PMID: 26388670 DOI: 10.3164/jcbn.15-14] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
104 Shepherd SJ, Halmos E, Glance S. The role of FODMAPs in irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. 2014;17:605-609. [PMID: 25255126 DOI: 10.1097/mco.0000000000000116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
105 Plavšić I, Hauser G, Tkalčić M, Pletikosić S, Salkić N. Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers. Gastroenterol Res Pract. 2015;2015:490183. [PMID: 26170833 DOI: 10.1155/2015/490183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
106 Iorio N, Malik Z, Schey R. Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol 2015;8:159-67. [PMID: 26089696 DOI: 10.2147/CEG.S67231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
107 Wang FY, Su M, Zheng YQ, Wang XG, Kang N, Chen T, Zhu EL, Bian ZX, Tang XD. Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. Acta Pharmacol Sin 2015;36:708-15. [PMID: 25960135 DOI: 10.1038/aps.2014.170] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
108 Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, Giannini EG, Savarino V. Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag 2015;11:691-703. [PMID: 26028974 DOI: 10.2147/TCRM.S54298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
109 Thomas RH, Luthin DR. Current and Emerging Treatments for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: Focus on Prosecretory Agents. Pharmacotherapy 2015;35:613-30. [DOI: 10.1002/phar.1594] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
110 Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr 2016;55:897-906. [DOI: 10.1007/s00394-015-0922-1] [Cited by in Crossref: 179] [Cited by in F6Publishing: 178] [Article Influence: 25.6] [Reference Citation Analysis]
111 Kavuri V, Raghuram N, Malamud A, Selvan SR. Irritable Bowel Syndrome: Yoga as Remedial Therapy. Evid Based Complement Alternat Med 2015;2015:398156. [PMID: 26064164 DOI: 10.1155/2015/398156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
112 Talley NJ, Holtmann G, Walker MM. Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. J Gastroenterol. 2015;50:601-613. [PMID: 25917563 DOI: 10.1007/s00535-015-1076-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
113 Li CY, Ain Mohd Tahir N, Li SC. A systematic review of integrated traditional Chinese and Western medicine for managing irritable bowel syndrome.Am J Chin Med. 2015;43:385-406. [PMID: 25916468 DOI: 10.1142/S0192415X15500251] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
114 Xiao Y, Liu Y, Huang S, Sun X, Tang Y, Cheng J, Wang T, Li F, Kuang Y, Luo R. The efficacy of Shugan Jianpi Zhixie therapy for diarrhea-predominant irritable bowel syndrome: a meta-analysis of randomized, double-blind, placebo-controlled trials. PLoS One. 2015;10:e0122397. [PMID: 25853241 DOI: 10.1371/journal.pone.0122397] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
115 Mendelson R. Imaging for chronic abdominal pain in adults. Aust Prescr 2015;38:49-54. [PMID: 26648616 DOI: 10.18773/austprescr.2015.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
116 Park R, Mikami S, LeClair J, Bollom A, Lembo C, Sethi S, Lembo A, Jones M, Cheng V, Friedlander E, Nurko S. Inpatient burden of childhood functional GI disorders in the USA: an analysis of national trends in the USA from 1997 to 2009. Neurogastroenterol Motil. 2015;27:684-692. [PMID: 25809794 DOI: 10.1111/nmo.12542] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
117 Good L, Rosario R, Panas R. New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin. World J Gastroenterol 2015; 21(11): 3361-3366 [PMID: 25805945 DOI: 10.3748/wjg.v21.i11.3361] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
118 Lu M, Zhang W, Yao Q, Lu XM, Li SL, Ju JM. Effect of Changkang Fang on serotonin transporter expression in brain-gut axis of visceral hypersensitive rats with irritable bowel syndrome. Shijie Huaren Xiaohua Zazhi 2015; 23(8): 1231-1237 [DOI: 10.11569/wcjd.v23.i8.1231] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
119 Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human Immunodeficiency Virus-Associated Diarrhea: Still an Issue in the Era of Antiretroviral Therapy. Dig Dis Sci. 2015;60:2236-2245. [PMID: 25772777 DOI: 10.1007/s10620-015-3615-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
120 Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444-454. [PMID: 25732419 DOI: 10.1038/ajg.2015.6] [Cited by in Crossref: 170] [Cited by in F6Publishing: 169] [Article Influence: 24.3] [Reference Citation Analysis]
121 McRorie JW Jr. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 2: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today 2015;50:90-7. [PMID: 25972619 DOI: 10.1097/NT.0000000000000089] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
122 Li CY, Li SC. Treatment of irritable bowel syndrome in China: A review. World J Gastroenterol 2015; 21(8): 2315-2322 [PMID: 25741137 DOI: 10.3748/wjg.v21.i8.2315] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
123 Korterink J, Devanarayana NM, Rajindrajith S, Vlieger A, Benninga MA. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2015;12:159-171. [PMID: 25666642 DOI: 10.1038/nrgastro.2015.21] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
124 Andresen V, Whorwell P, Fortea J, Auzière S. An exploration of the barriers to the confident diagnosis of irritable bowel syndrome: A survey among general practitioners, gastroenterologists and experts in five European countries. United European Gastroenterol J 2015;3:39-52. [PMID: 25653858 DOI: 10.1177/2050640614558344] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
125 Aro P, Talley NJ, Johansson SE, Agréus L, Ronkainen J. Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study. Gastroenterology 2015;148:928-37. [PMID: 25644097 DOI: 10.1053/j.gastro.2015.01.039] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 10.6] [Reference Citation Analysis]
126 Laghi A. Computed tomography colonography in 2014: An update on technique and indications. World J Gastroenterol 2014; 20(45): 16858-16867 [PMID: 25492999 DOI: 10.3748/wjg.v20.i45.16858] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
127 Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J 2014;2:505-12. [PMID: 25452846 DOI: 10.1177/2050640614554217] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
128 Pedersen N, Andersen NN, Végh Z, Jensen L, Ankersen DV, Felding M, Simonsen MH, Burisch J, Munkholm P. Ehealth: Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 2014; 20(43): 16215-16226 [PMID: 25473176 DOI: 10.3748/wjg.v20.i43.16215] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 97] [Article Influence: 14.0] [Reference Citation Analysis]
129 Spencer M, Chey WD, Eswaran S. Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy? Curr Treat Options Gastroenterol 2014;12:424-40. [PMID: 25219357 DOI: 10.1007/s11938-014-0031-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
130 Ryoo SB, Oh HK, Yu SA, Moon SH, Choe EK, Oh TY, Park KJ. The effects of eupatilin (stillen®) on motility of human lower gastrointestinal tracts. Korean J Physiol Pharmacol 2014;18:383-90. [PMID: 25352757 DOI: 10.4196/kjpp.2014.18.5.383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
131 Collebrusco L, Lombardini R. What about OMT and nutrition for managing the irritable bowel syndrome? An overview and treatment plan. Explore (NY) 2014;10:309-18. [PMID: 25224307 DOI: 10.1016/j.explore.2014.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
132 Soares RL. Irritable bowel syndrome: A clinical review. World J Gastroenterol 2014; 20(34): 12144-12160 [PMID: 25232249 DOI: 10.3748/wjg.v20.i34.12144] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 93] [Article Influence: 13.1] [Reference Citation Analysis]
133 Gonzalez-Martinez MA, Ortiz-Olvera NX, Mendez-Navarro J. Novel pharmacological therapies for management of chronic constipation. J Clin Gastroenterol. 2014;48:21-28. [PMID: 24172177 DOI: 10.1097/01.mcg.0000436440.05887.02] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
134 Yu SW, Rao SS. Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol. 2014;7:193-205. [PMID: 25177366 DOI: 10.1177/1756283x14537882] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
135 Kim YI, Poudel BK, Pradhan R, Choi H, Yong CS, Woo JS, Kim JO. Development of a novel bi-coated combination capsule containing mosapride and probiotics for irritable bowel syndrome. Pharmaceutical Development and Technology 2014;20:949-56. [DOI: 10.3109/10837450.2014.954723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Slim M, Calandre EP, Rico-Villademoros F. An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms. Rheumatol Int 2015;35:433-44. [PMID: 25119830 DOI: 10.1007/s00296-014-3109-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
137 Breen M, Murphy KP, O’neill SB, O’donovan JP, Mcwilliams S, Desmond AN, Shanahan F, Quigley EM, Maher MM. The utilisation and diagnostic yield of radiological imaging in a specialist functional GI disorder clinic: an 11-year retrospective study. Eur Radiol 2014;24:3097-104. [DOI: 10.1007/s00330-014-3315-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
138 Zullo A, Hassan C, Francesco VD, Repici A, Manta R, Tomao S, Annibale B, Vaira D. Helicobacter pylori and functional dyspepsia: An unsolved issue? World J Gastroenterol 2014; 20(27): 8957-8963 [PMID: 25083068 DOI: 10.3748/wjg.v20.i27.8957] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
139 Solga SF. Breath volatile organic compounds for the gut-fatty liver axis: Promise, peril, and path forward. World J Gastroenterol 2014; 20(27): 9017-9025 [PMID: 25083075 DOI: 10.3748/wjg.v20.i27.9017] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
140 Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: A concise review of current treatment concepts. World J Gastroenterol 2014; 20(27): 8796-8806 [PMID: 25083054 DOI: 10.3748/wjg.v20.i27.8796] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
141 Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: A concise review of current treatment concepts. WJG 2014;20:8796-806. [DOI: 10.3748/wjg.v20.i27.5796] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Jadallah KA, Kullab SM, Sanders DS. Constipation-predominant irritable bowel syndrome: A review of current and emerging drug therapies. World J Gastroenterol 2014; 20(27): 8898-8909 [PMID: 25083062 DOI: 10.3748/wjg.v20.i27.8898] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
143 Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 2014; 20(27): 8807-8820 [PMID: 25083055 DOI: 10.3748/wjg.v20.i27.8807] [Cited by in F6Publishing: 39] [Reference Citation Analysis]
144 Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20(27): 8867-8885 [PMID: 25083060 DOI: 10.3748/wjg.v20.i27.8867] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
145 Wang XX, Luo RJ, She B, Chen Y, Guo J. Traditional Chinese medicine (Shun-Qi-Tong-Xie Granule) for irritable bowel syndrome: study protocol for a randomised controlled trial. Trials 2014;15:273. [PMID: 25002196 DOI: 10.1186/1745-6215-15-273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, Hashemi H, Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res. 2014;3:140. [PMID: 25161987 DOI: 10.4103/2277-9175.135157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
147 Shah E, Pimentel M. Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil. 2014;20:163-170. [PMID: 24840369 DOI: 10.5056/jnm.2014.20.2.163] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
148 Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(22): 6759-6773 [PMID: 24944467 DOI: 10.3748/wjg.v20.i22.6759] [Cited by in CrossRef: 170] [Cited by in F6Publishing: 141] [Article Influence: 21.3] [Reference Citation Analysis]
149 Magge SS, Wolf JL. Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women. Womens Health (Lond) 2013;9:557-67. [PMID: 24161308 DOI: 10.2217/whe.13.57] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
150 Rutten JM, Vlieger AM, Frankenhuis C, George EK, Groeneweg M, Norbruis OF, Tjon a Ten W, Van Wering H, Dijkgraaf MG, Merkus MP, Benninga MA. Gut-directed hypnotherapy in children with irritable bowel syndrome or functional abdominal pain (syndrome): a randomized controlled trial on self exercises at home using CD versus individual therapy by qualified therapists. BMC Pediatr 2014;14:140. [PMID: 24894077 DOI: 10.1186/1471-2431-14-140] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
151 Goepp J, Fowler E, McBride T, Landis D. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. Glob Adv Health Med. 2014;3:9-15. [PMID: 24891989 DOI: 10.7453/gahmj.2013.099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
152 Parsons K, Goepp J, Dechairo B, Fowler E, Markward N, Hanaway P, McBride T, Landis D. Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study. Glob Adv Health Med 2014;3:25-32. [PMID: 24891991 DOI: 10.7453/gahmj.2013.100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
153 Manning DD, Guo C, Zhang Z, Ryan KN, Naginskaya J, Choo SH, Masih L, Earley WG, Wierschke JD, Newman AS, Brady CA, Barnes NM, Guzzo PR. The discovery of diazepinone-based 5-HT3 receptor partial agonists. Bioorganic & Medicinal Chemistry Letters 2014;24:2578-81. [DOI: 10.1016/j.bmcl.2014.03.074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
154 Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol. 2014;49:1193-1205. [PMID: 24845149 DOI: 10.1007/s00535-014-0966-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
155 Tuck CJ, Muir JG, Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:819-834. [PMID: 24830318 DOI: 10.1586/17474124.2014.917956] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 9.0] [Reference Citation Analysis]
156 Andrae DA, Covington PS, Patrick DL. Item-Level Assessment of the Irritable Bowel Syndrome Quality of Life Questionnaire in Patients With Diarrheal Irritable Bowel Syndrome. Clinical Therapeutics 2014;36:663-79. [DOI: 10.1016/j.clinthera.2014.04.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
157 Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161-1168. [PMID: 24697851 DOI: 10.1111/apt.12735] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
158 Siah KTH, Wong RKM, Ho KY. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20(10): 2492-2498 [PMID: 24627586 DOI: 10.3748/wjg.v20.i10.2492] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
159 Chang FY. Irritable bowel syndrome: The evolution of multi-dimensional looking and multidisciplinary treatments. World J Gastroenterol 2014; 20(10): 2499-2514 [PMID: 24627587 DOI: 10.3748/wjg.v20.i10.2499] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
160 Chao GQ, Zhang S. Effectiveness of acupuncture to treat irritable bowel syndrome: A meta-analysis. World J Gastroenterol 2014; 20(7): 1871-1877 [PMID: 24587665 DOI: 10.3748/wjg.v20.i7.1871] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
161 Stanghellini V. Perspectives on irritable bowel syndrome: where have we been? Where are we now? Expert Rev Gastroenterol Hepatol 2013;7:3-7. [PMID: 23859754 DOI: 10.1586/17474124.2013.820050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Layer P, Stanghellini V. Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014;39:371-384. [PMID: 24433216 DOI: 10.1111/apt.12604] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
163 Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J Gastroenterol 2014; 20(2): 346-362 [PMID: 24574705 DOI: 10.3748/wjg.v20.i2.346] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.9] [Reference Citation Analysis]
164 Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol 2014; 20(2): 363-375 [PMID: 24574706 DOI: 10.3748/wjg.v20.i2.363] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
165 Layer P. Management of irritable bowel syndrome with constipation: a flexible approach to treating a complex condition with multiple symptoms. Expert Review of Gastroenterology & Hepatology 2014;7:9-14. [DOI: 10.1586/17474124.2013.820049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013;8:350-3. [PMID: 24868283 DOI: 10.5114/pg.2013.39917] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
167 Lee KN, Lee OY, Choi MG, Sohn CI, Huh KC, Park KS, Kwon JG, Kim N, Rhee PL, Myung SJ. Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium. J Neurogastroenterol Motil. 2014;20:113-121. [PMID: 24466452 DOI: 10.5056/jnm.2014.20.1.113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
168 Lacy BE, Lembo AJ, Macdougall JE, Shiff SJ, Kurtz CB, Currie MG, Johnston JM. Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C. Neurogastroenterol Motil 2014;26:326-33. [PMID: 24382134 DOI: 10.1111/nmo.12264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
169 Ma YX, Liu X, Liu CZ, Wang LP, Guo G, Du DQ, Wang ZL, Ma H, Qi P, Li ZF. Randomized clinical trial: the clinical effects of herb-partitioned moxibustion in patients with diarrhoea-predominant irritable bowel syndrome. Evid Based Complement Alternat Med. 2013;2013:605460. [PMID: 24454500 DOI: 10.1155/2013/605460] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
170 Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes 2013;11:208. [PMID: 24330412 DOI: 10.1186/1477-7525-11-208] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
171 Thomaidis T, Goetz M, Gregor SP, Hoffman A, Kouroumalis E, Moehler M, Galle PR, Schwarting A, Kiesslich R. Irritable bowel syndrome and organic diseases: A comparative analysis of esophageal motility. World J Gastroenterol 2013; 19(38): 6408-6415 [PMID: 24151359 DOI: 10.3748/wjg.v19.i38.6408] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
172 Park JW, Lee BH, Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complement Altern Med 2013;13:247. [PMID: 24088418 DOI: 10.1186/1472-6882-13-247] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
173 Scalera A, Di Minno MND, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19(33): 5402-5420 [PMID: 24023483 DOI: 10.3748/wjg.v19.i33.5402] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
174 Pohl D, Heinrich H, Misselwitz B. Reizdarmsyndrom – Diagnostik und Therapie. Gastroenterologe 2013;8:417-24. [DOI: 10.1007/s11377-013-0783-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
175 Anastasi JK, Capili B, Chang M. Managing irritable bowel syndrome. Am J Nurs 2013;113:42-52; quiz 54, 53. [PMID: 23764698 DOI: 10.1097/01.NAJ.0000431911.65473.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
176 Bucci C, Tremolaterra F, Gallotta S, Fortunato A, Cappello C, Ciacci C, Iovino P. A pilot study on the effect of a symbiotic mixture in irritable bowel syndrome: an open-label, partially controlled, 6-month extension of a previously published trial. Tech Coloproctol. 2014;18:345-353. [PMID: 23922211 DOI: 10.1007/s10151-013-1055-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
177 Parker CH, Yuan Y, Liu LW. Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults. Clin Med Insights Gastroenterol 2013;6:21-32. [PMID: 24833940 DOI: 10.4137/CGast.S10550] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
178 Chang FY, Lu CL. Irritable bowel syndrome and migraine: bystanders or partners? J Neurogastroenterol Motil. 2013;19:301-311. [PMID: 23875096 DOI: 10.5056/jnm.2013.19.3.301] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
179 Kok L, Elias SG, Witteman BJ, Goedhard JG, Romberg-camps MJ, Muris JW, Moons KG, de Wit NJ. Application of the Rome III criteria is not likely to reduce the number of unnecessary referrals for colonoscopy in primary care: . European Journal of Gastroenterology & Hepatology 2013;25:568-74. [DOI: 10.1097/meg.0b013e32835d4ddd] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
180 Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K, Shah R, Atia M, Kurzbard N, Sheen V. Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol. 2013;11:1614-1619. [PMID: 23524129 DOI: 10.1016/j.cgh.2013.03.007] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
181 Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25:46-52. [PMID: 23449495 DOI: 10.1055/s-0032-1301759] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
182 Sandhu DK, Surawicz C. Update on chronic diarrhea: a run-through for the clinician. Curr Gastroenterol Rep 2012;14:421-7. [PMID: 22903799 DOI: 10.1007/s11894-012-0283-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
183 Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714-1724; quiz 1725. [PMID: 22986440 DOI: 10.1038/ajg.2012.255] [Cited by in Crossref: 227] [Cited by in F6Publishing: 230] [Article Influence: 25.2] [Reference Citation Analysis]
184 Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714-1724; quiz p.1725. [PMID: 22986440 DOI: 10.1038/ajg/2012.255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Colucci R, Gambaccini D, Ghisu N, Rossi G, Costa F, Tuccori M, De Bortoli N, Fornai M, Antonioli L, Ricchiuti A. Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. PLoS One. 2013;8:e54831. [PMID: 23393559 DOI: 10.1371/journal.pone.0054831] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
186 De Ponti F. Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol. 2013;4:7. [PMID: 23378837 DOI: 10.3389/fphar.2013.00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
187 Craig OF, Quigley EM. Current and emerging therapies for the management of functional gastrointestinal disorders. Ther Adv Chronic Dis 2011;2:87-99. [PMID: 23251744 DOI: 10.1177/2040622310389507] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
188 Grover M, Camilleri M. Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. J Gastroenterol. 2013;48:177-181. [PMID: 23254779 DOI: 10.1007/s00535-012-0726-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
189 Chutkan R, Fahey G, Wright WL, McRorie J. Viscous versus nonviscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits. J Am Acad Nurse Pract. 2012;24:476-487. [PMID: 22845031 DOI: 10.1111/j.1745-7599.2012.00758.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
190 Labus J, Gupta A, Gill HK, Posserud I, Mayer M, Raeen H, Bolus R, Simren M, Naliboff BD, Mayer EA. Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Aliment Pharmacol Ther. 2013;37:304-315. [PMID: 23205588 DOI: 10.1111/apt.12171] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
191 Goo YA, Cain K, Jarrett M, Smith L, Voss J, Tolentino E, Tsuji J, Tsai YS, Panchaud A, Goodlett DR, Shulman RJ, Heitkemper M. Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups. J Proteome Res 2012;11:5650-62. [PMID: 22998556 DOI: 10.1021/pr3004437] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
192 Palsson OS, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol Hepatol. 2013;11:208-16; quiz e22-3. [PMID: 23103907 DOI: 10.1016/j.cgh.2012.10.031] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 8.5] [Reference Citation Analysis]
193 El-Salhy M. Irritable bowel syndrome: Diagnosis and pathogenesis. World J Gastroenterol 2012; 18(37): 5151-5163 [PMID: 23066308 DOI: 10.3748/wjg.v18.i37.5151] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 104] [Article Influence: 7.4] [Reference Citation Analysis]
194 Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. 2012;5:23-30. [PMID: 22282705 DOI: 10.1177/1756283x11423706] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
195 Sinagra E, Romano C, Cottone M. Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterol Res Pract. 2012;2012:486067. [PMID: 22956940 DOI: 10.1155/2012/486067] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
196 Kheraj R, Tewani SK, Ketwaroo G, Leffler DA. Quality improvement in gastroenterology clinical practice. Clin Gastroenterol Hepatol. 2012;10:1305-1314. [PMID: 22902758 DOI: 10.1016/j.cgh.2012.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
197 Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18(30): 4012-4018 [PMID: 22912552 DOI: 10.3748/wjg.v18.i30.4012] [Cited by in CrossRef: 155] [Cited by in F6Publishing: 133] [Article Influence: 15.5] [Reference Citation Analysis]
198 Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis. 2013;28:349-358. [PMID: 22885882 DOI: 10.1007/s00384-012-1552-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
199 Wang YT, Lim HY, Tai D, Krishnamoorthy TL, Tan T, Barbier S, Thumboo J. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 2012;12:104. [PMID: 22873839 DOI: 10.1186/1471-230x-12-104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
200 Camilleri M, Di Lorenzo C. Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr. 2012;54:446-453. [PMID: 22027566 DOI: 10.1097/mpg.0b013e31823d34c3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
201 Ringel Y, Quigley EM, Lin HC. Using Probiotics in Gastrointestinal Disorders. Am J Gastroenterol Suppl 2012;1:34-40. [DOI: 10.1038/ajgsup.2012.7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
202 Collins SM, Chang C, Mearin F. Postinfectious Chronic Gut Dysfunction: From Bench to Bedside. Am J Gastroenterol Suppl 2012;1:2-8. [DOI: 10.1038/ajgsup.2012.2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
203 Koo HL, Sabounchi S, Huang DB, DuPont HL. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012;5:31-41. [PMID: 24833932 DOI: 10.4137/CGast.S7382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
204 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
205 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S29023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
206 Zernicke KA, Campbell TS, Blustein PK, Fung TS, Johnson JA, Bacon SL, Carlson LE. Mindfulness-Based Stress Reduction for the Treatment of Irritable Bowel Syndrome Symptoms: A Randomized Wait-list Controlled Trial. Int J Behav Med 2013;20:385-96. [DOI: 10.1007/s12529-012-9241-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 9.1] [Reference Citation Analysis]
207 Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. [PMID: 22592702 DOI: 10.1002/14651858.cd005111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
208 Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. [PMID: 22592702 DOI: 10.1002/14651858.cd005111.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
209 Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;5:CD005111. [PMID: 22592702 DOI: 10.10002/14651858.CD005111.pub3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Paulson JD. Abdominal and urogenital diseases can often be the cause of lower back pain and sciatic-like symptoms. Pain Management 2012;2:279-94. [DOI: 10.2217/pmt.12.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
211 Hauser G, Tkalcic M, Pletikosic S, Grabar N, Stimac D. Erythrocyte sedimentation rate - possible role in determining the existence of the low grade inflammation in Irritable Bowel Syndrome patients. Med Hypotheses. 2012;78:818-820. [PMID: 22513237 DOI: 10.1016/j.mehy.2012.03.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
212 Ciorba MA. A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol. 2012;10:960-968. [PMID: 22504002 DOI: 10.1016/j.cgh.2012.03.024] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
213 Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, Lao L. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:835-47; quiz 848. [PMID: 22488079 DOI: 10.1038/ajg.2012.66] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
214 McKenzie YA, Alder A, Anderson W, Wills A, Goddard L, Gulia P, Jankovich E, Mutch P, Reeves LB, Singer A. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet. 2012;25:260-274. [PMID: 22489905 DOI: 10.1111/j.1365-277x.2012.01242.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 8.4] [Reference Citation Analysis]
215 Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil 2012;18:200-4. [PMID: 22523730 DOI: 10.5056/jnm.2012.18.2.200] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
216 Ishihara S, Yashima K, Kushiyama Y, Izumi A, Kawashima K, Fujishiro H, Kojo H, Komazawa Y, Hamamoto T, Yamamoto T. Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy. J Gastroenterol. 2012;47:1084-1090. [PMID: 22460220 DOI: 10.1007/s00535-012-0573-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
217 Butt AS, Salih M, Jafri W, Yakoob J, Wasay M, Hamid S. Irritable bowel syndrome and psychiatric disorders in pakistan: a case control study. Gastroenterol Res Pract 2012;2012:291452. [PMID: 22505882 DOI: 10.1155/2012/291452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
218 Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:521-30, e248. [PMID: 22339879 DOI: 10.1111/j.1365-2982.2012.01891.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 243] [Article Influence: 23.3] [Reference Citation Analysis]
219 Häuser W, Layer P, Henningsen P, Kruis W. Functional bowel disorders in adults. Dtsch Arztebl Int 2012;109:83-94. [PMID: 22368721 DOI: 10.3238/arztebl.2012.0083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
220 Guandalini S, Newland C. Differentiating food allergies from food intolerances. Curr Gastroenterol Rep 2011;13:426-34. [PMID: 21792544 DOI: 10.1007/s11894-011-0215-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
221 Mangel AW, Hicks GA. Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review. Clin Exp Gastroenterol. 2012;5:1-10. [PMID: 22346361 DOI: 10.2147/ceg.s23274] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
222 Shepherd A. The role of diet in the management of IBS. Nurse Prescribing 2012;10:32-7. [DOI: 10.12968/npre.2012.10.1.32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
223 Spiller RC, Thompson WG. [NO TITLE AVAILABLE]. Arq Gastroenterol 2012;49:39-50. [DOI: 10.1590/s0004-28032012000500008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
224 Wensel TM, Luthin DR. Linaclotide: A Novel Approach to the Treatment of Irritable Bowel Syndrome. Ann Pharmacother 2011;45:1535-43. [DOI: 10.1345/aph.1q428] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
225 Talley NJ, Fodor AA. Bugs, Stool, and the Irritable Bowel Syndrome: Too Much Is as Bad as Too Little? Gastroenterology 2011;141:1555-9. [DOI: 10.1053/j.gastro.2011.09.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
226 Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17:402-410. [PMID: 22148110 DOI: 10.5056/jnm.2011.17.4.402] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
227 Oxentenko AS, Bundrick JB, Litin SC. Clinical pearls in gastroenterology 2011. Mayo Clin Proc 2011;86:1104-8. [PMID: 22033255 DOI: 10.4065/mcp.2011.0399] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
228 Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol. 2011;45:518-525. [PMID: 21436726 DOI: 10.1097/mcg.0b013e31820ca4d6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 97] [Article Influence: 9.0] [Reference Citation Analysis]
229 Leffler D. Celiac disease diagnosis and management: a 46-year-old woman with anemia. JAMA 2011;306:1582-92. [PMID: 21990301 DOI: 10.1001/jama.306.14.1582] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
230 Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011;34:545-65. [PMID: 21663331 DOI: 10.2165/11590690-000000000-00000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
231 Agrawal A, Whorwell P. Treatment of bloating and distension - role of probiotics. Aliment Pharmacol Ther 2011;34:580-1; author reply 581-3. [PMID: 21806643 DOI: 10.1111/j.1365-2036.2011.04766.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Dickman R, Segev M, Levi S, Reicher-atir R, Steinmetz A, Horev N, Niv Y. Perceptions of gastroenterologists and nurses regarding irritable bowel syndrome and inflammatory bowel disease: . European Journal of Gastroenterology & Hepatology 2011;23:813-7. [DOI: 10.1097/meg.0b013e328348a552] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
233 Ozdil K, Sahin A, Calhan T, Kahraman R, Nigdelioglu A, Akyuz U, Sokmen HM. The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome. BMC Gastroenterol. 2011;11:96. [PMID: 21880133 DOI: 10.1186/1471-230x-11-96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
234 Ladabaum U, Boyd E, Zhao WK, Mannalithara A, Sharabidze A, Singh G, Chung E, Levin TR. Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol. 2012;10:37-45. [PMID: 21871250 DOI: 10.1016/j.cgh.2011.08.015] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
235 Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5:253-66. [PMID: 21927652 DOI: 10.5009/gnl.2011.5.3.253] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
236 Cash BD, Rubenstein JH, Young PE, Gentry A, Nojkov B, Lee D, Andrews AH, Dobhan R, Chey WD. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-1193. [PMID: 21762658 DOI: 10.1053/j.gastro.2011.06.084] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 7.3] [Reference Citation Analysis]
237 Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010;1:97-105. [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol 2010;3:165-72. [PMID: 21180598 DOI: 10.1177/1756283X10362277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
239 Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther. 2011;33:812-827. [PMID: 21741091 DOI: 10.1016/j.clinthera.2011.06.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
240 Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G. Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents. Cochrane Database Syst Rev 2011;:CD008013. [PMID: 21735420 DOI: 10.1002/14651858.CD008013.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
241 Getto L, Zeserson E, Breyer M. Vomiting, diarrhea, constipation, and gastroenteritis. Emerg Med Clin North Am 2011;29:211-37, vii-viii. [PMID: 21515177 DOI: 10.1016/j.emc.2011.01.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
242 Quigley EM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol. 2011;25:119-126. [PMID: 21382583 DOI: 10.1016/j.bpg.2011.01.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
243 Gaylord SA, Palsson OS, Garland EL, Faurot KR, Coble RS, Mann JD, Frey W, Leniek K, Whitehead WE. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol. 2011;106:1678-1688. [PMID: 21691341 DOI: 10.1038/ajg.2011.184] [Cited by in Crossref: 149] [Cited by in F6Publishing: 151] [Article Influence: 13.5] [Reference Citation Analysis]
244 Armstrong D, Don-Wauchope AC, Verdu EF. Testing for gluten-related disorders in clinical practice: the role of serology in managing the spectrum of gluten sensitivity. Can J Gastroenterol. 2011;25:193-197. [PMID: 21523259 DOI: 10.1155/2011/642452] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
245 Abdulmajeed A, Rabab MA, Sliem HA, Hebatallah NE. Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt. Pan Afr Med J 2011;9:5. [PMID: 22145053 DOI: 10.4314/pamj.v9i1.71177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
246 Chiou E, Nurko S. Functional abdominal pain and irritable bowel syndrome in children and adolescents. Therapy 2011;8:315-31. [DOI: 10.2217/thy.11.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
247 Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011;4:43-8. [PMID: 21694871 DOI: 10.2147/CEG.S18051] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
248 Cabré E. Clinical Nutrition University: Nutrition in the prevention and management of irritable bowel syndrome, constipation and diverticulosis. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 2011;6:e85-95. [DOI: 10.1016/j.eclnm.2011.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
249 Chang F, Lu C. The clinical significances of irritable bowel syndrome in Taiwan: IBS in Taiwan. Journal of Gastroenterology and Hepatology 2011;26:102-5. [DOI: 10.1111/j.1440-1746.2011.06646.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
250 Aro P, Talley NJ, Agréus L, Johansson SE, Bolling-Sternevald E, Storskrubb T, Ronkainen J. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther. 2011;33:1215-1224. [PMID: 21443537 DOI: 10.1111/j.1365-2036.2011.04640.x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 11.2] [Reference Citation Analysis]
251 Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9:461-469; quiz e59. [PMID: 21397724 DOI: 10.1016/j.cgh.2011.02.030] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
252 Machu TK. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther. 2011;130:338-347. [PMID: 21356241 DOI: 10.1016/j.pharmthera.2011.02.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
253 Kopelman Y, Triadafilopoulos G. Endoscopy in the Diagnosis and Management of Motility Disorders. Dig Dis Sci 2011;56:635-54. [DOI: 10.1007/s10620-011-1584-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
254 Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol. 2010;7:565-581. [PMID: 20890316 DOI: 10.1038/nrgastro.2010.137] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 7.1] [Reference Citation Analysis]
255 Chen MX, Cai G. Evaluation of health-related quality of life in patients with irritable bowel syndrome: research status and prospects. Shijie Huaren Xiaohua Zazhi 2011; 19(1): 1-6 [DOI: 10.11569/wcjd.v19.i1.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5:e15591. [PMID: 21203519 DOI: 10.1371/journal.pone.0015591] [Cited by in Crossref: 467] [Cited by in F6Publishing: 404] [Article Influence: 38.9] [Reference Citation Analysis]
257 Kellow JE. IBS: Do we need to exclude exocrine pancreatic insufficiency in IBS? Nat Rev Gastroenterol Hepatol 2010;7:479-80. [PMID: 20811362 DOI: 10.1038/nrgastro.2010.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
258 Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil. 2011;23:193-200. [PMID: 21159063 DOI: 10.1111/j.1365-2982.2010.01643.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
259 Nelson TA, Holmes S, Alekseyenko AV, Shenoy M, Desantis T, Wu CH, Andersen GL, Winston J, Sonnenburg J, Pasricha PJ, Spormann A. PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. Neurogastroenterol Motil 2011;23:169-77, e41-2. [PMID: 21129126 DOI: 10.1111/j.1365-2982.2010.01637.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
260 Manning DD, Cioffi CL, Usyatinsky A, Fitzpatrick K, Masih L, Guo C, Zhang Z, Choo SH, Sikkander MI, Ryan KN, Naginskaya J, Hassler C, Dobritsa S, Wierschke JD, Earley WG, Butler AS, Brady CA, Barnes NM, Cohen ML, Guzzo PR. Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome. Bioorg Med Chem Lett 2011;21:58-61. [PMID: 21146988 DOI: 10.1016/j.bmcl.2010.11.080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
261 Spiegel BM, Bolus R, Agarwal N, Sayuk G, Harris LA, Lucak S, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Talley J, Chang L. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther 2010;32:1275-91. [PMID: 20955447 DOI: 10.1111/j.1365-2036.2010.04464.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
262 Chiou E, Nurko S. Management of functional abdominal pain and irritable bowel syndrome in children and adolescents. Expert Rev Gastroenterol Hepatol. 2010;4:293-304. [PMID: 20528117 DOI: 10.1586/egh.10.28] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
263 Burbige EJ. Irritable bowel syndrome: diagnostic approaches in clinical practice. Clin Exp Gastroenterol. 2010;3:127-137. [PMID: 21694856 DOI: 10.2147/ceg.s12596] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
264 Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O’Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877-1886.e2. [PMID: 20801122 DOI: 10.1053/j.gastro.2010.08.041] [Cited by in Crossref: 152] [Cited by in F6Publishing: 154] [Article Influence: 12.7] [Reference Citation Analysis]
265 Trinkley KE, Nahata MC. Treatment of irritable bowel syndrome. J Clin Pharm Ther 2011;36:275-82. [PMID: 21545610 DOI: 10.1111/j.1365-2710.2010.01177.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
266 Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010; 1(3): 97-105 [PMID: 21607147 DOI: 10.4291/wjgp.v1.i3.97] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
267 Huang X, Lv B. Diagnosis and treatment of irritable bowel syndrome: advances and challenges. Shijie Huaren Xiaohua Zazhi 2010; 18(21): 2234-2239 [DOI: 10.11569/wcjd.v18.i21.2234] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
268 Ford AC. Renzapride in IBS: is efficacy in the eye of the beholder? Aliment Pharmacol Ther 2010;32:113-4; author reply 114-5. [PMID: 20597877 DOI: 10.1111/j.1365-2036.2010.04275.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
269 Camilleri M. Review article: new receptor targets for medical therapy in irritable bowel syndrome. Aliment Pharmacol Ther. 2010;31:35-46. [PMID: 19785622 DOI: 10.1111/j.1365-2036.2009.04153.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
270 Ford AC. Alverine citrate, simeticone, and Rome III irritable bowel syndrome. Aliment Pharmacol Ther 2010;31:767-8; author reply 768-9. [PMID: 20415841 DOI: 10.1111/j.1365-2036.2009.04222.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
271 Ford AC. Probiotics in irritable bowel syndrome: underachievers or underpowered?: LETTERS TO THE EDITORS. Alimentary Pharmacology & Therapeutics 2010;31:922-3. [DOI: 10.1111/j.1365-2036.2009.04223.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
272 Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848-858. [PMID: 20197761 DOI: 10.1038/ajg.2010.47] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 8.6] [Reference Citation Analysis]
273 Chey WD, Nojkov B, Rubenstein JH, Dobhan RR, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-865. [PMID: 20179696 DOI: 10.1038/ajg.2010.55] [Cited by in Crossref: 99] [Cited by in F6Publishing: 100] [Article Influence: 8.3] [Reference Citation Analysis]
274 Whitehead WE, Drossman DA. Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol. 2010;105:814-20; quiz 813, 821. [PMID: 20179688 DOI: 10.1038/ajg.2010.56] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 6.0] [Reference Citation Analysis]
275 Lackner JM, Gudleski GD, Keefer L, Krasner SS, Powell C, Katz LA. Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8:426-432. [PMID: 20170751 DOI: 10.1016/j.cgh.2010.02.007] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
276 Longstreth GF. Symptoms and Tests for Irritable Bowel Syndrome: Diagnosing a Complex Disorder. Clinical Gastroenterology and Hepatology 2010;8:132-6. [DOI: 10.1016/j.cgh.2009.10.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
277 Quigley EM. Prebiotics for irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2009;3:487-92. [PMID: 19817670 DOI: 10.1586/egh.09.46] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
278 Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, Jin C, Grimes B, Pepin CJ. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8:42-48.e1. [PMID: 19765674 DOI: 10.1016/j.cgh.2009.09.008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
279 Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, Jin C, Grimes B, Pepin CJ. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8:42-48.e1. [PMID: 19765674 DOI: 10.1016/j.cgh.2009.09.008.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 Rezzi S, Martin F, Alonso C, Guilarte M, Vicario M, Ramos L, Martínez C, Lobo B, Saperas E, Malagelada JR, Santos J, Kochhar S. Metabotyping of Biofluids Reveals Stress-Based Differences in Gut Permeability in Healthy Individuals. J Proteome Res 2009;8:4799-809. [DOI: 10.1021/pr900525w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
281 Spiegel B, Harris L, Lucak S, Mayer E, Naliboff B, Bolus R, Esrailian E, Chey WD, Lembo A, Karsan H, Tillisch K, Dulai G, Talley J, Chang L. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009;104:1984-91. [PMID: 19491835 DOI: 10.1038/ajg.2009.232] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
282 Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43; quiz 1844. [PMID: 19471254 DOI: 10.1038/ajg.2009.223] [Cited by in Crossref: 193] [Cited by in F6Publishing: 165] [Article Influence: 14.8] [Reference Citation Analysis]